IDEXX Laboratories Inc (NASDAQ: IDXX) has reported E.P.S. of $2.84 for its first fiscal quarter (ending March 31) versus $2.58 for the same period a year ago — an increase of 10%. However, this result fell short of the consensus estimate of $3.11 by $-0.27. For the latest four quarters through March 31, E.P.S. were $10.43 compared to $8.40 a year ago — an increase of 24%.
Recent Price Action
IDEXX Laboratories Inc (NASDAQ: IDXX) stock closed at $468.04 on 5/1/24 after a large decline of -5.0%. Moreover, exceptionally high trading volume at 239% of normal accompanied the decline. The stock has declined -5.2% during the last week but has been strong relative to the market over the last nine months.
Current PriceTarget Research Rating
IDXX is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.
IDEXX Laboratories has a current Value Trend Rating of C (Low Neutral). This rating combines contradictory signals from two proprietary PTR measures of a stock’s attractiveness. IDEXX Laboratories has a poor Appreciation Score of 24 but a slightly positive Power Rating of 66, resulting in the Low Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment